Advertisement
Singapore markets closed

  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     

  • S&P 500

    5,078.98
    +8.43 (+0.17%)
     

  • Dow

    38,472.09
    -31.60 (-0.08%)
     

  • Nasdaq

    15,786.58
    +89.94 (+0.57%)
     

  • Bitcoin USD

    65,354.87
    -1,530.72 (-2.29%)
     

  • CMC Crypto 200

    1,426.99
    +2.89 (+0.20%)
     

  • FTSE 100

    8,050.39
    +5.58 (+0.07%)
     

  • Gold

    2,334.40
    -7.70 (-0.33%)
     

  • Crude Oil

    82.89
    -0.47 (-0.56%)
     

  • 10-Yr Bond

    4.6580
    +0.0600 (+1.30%)
     

  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     

  • Jakarta Composite Index

    7,174.53
    +63.72 (+0.90%)
     

  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Evolus to Report Third Quarter 2021 Results and Provide Business Update

Evolus
·2-min read

NEWPORT BEACH, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its third quarter 2021 financial results and provide a business update on Tuesday, November 2, 2021, prior to the open of the U.S. financial markets.

Management will host a conference call and live webcast to discuss Evolus’ financial results at 9:00 a.m. ET that same day. A question-and-answer session will follow management’s remarks.

To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect to the live webcast via the link on the Investor Relations page of the Evolus website at www.evolus.com.

Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international). An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.

ADVERTISEMENT

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com.

Jeuveau® is a registered trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Evolus, Inc. Contacts:

Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com